| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 28(3); 1996 > Article
Journal of the Korean Cancer Association 1996;28(3): 573-582.
정맥주사용 그라니세트론 1 일 또는 2 일 투여가 Cisplatin 을 포함한 항암요법시 오심구토의 예방과 Quality of Life 에 미치는 영향
민우성, 문한림, 강진형, 진종률, 김춘추, 김동집, 주성자, 강경심, 유재분
Effect of One - day ( G1 ) and Two - day ( G2 ) Schedule of Intravenous Granisetron on Prevention of nausea and Vomiting and Qualit Of Life during Cisplatin - Containin
Woo Sung Min, Han Lim Moon, Jin Hyoung Kang, Jong Youl Jin, Choon Choo Kim, Dong Jip Kim, Seong Ja Choo, Kyung Shim Kang, Jae Boon Ryu
Background: Nausea/vomiting is one of the most important item on deterioration of quality of life(QOL) in patients with cisplatin-containing chematherapy and may ultimately result in delay or refusal of the next chemotherapy. Although 5-hydroxy tryptamine 3(5-HT3) antagonist, ondansetron successfully controls cisplatin-induced nausea/vomiting during the first 24 hours, it fails to control nausea/vomiting on the following 24 hours in many patients. Authors performed this study to compare the effect of one-day and two-day schedule of intravenous granisetron on prevention of cisplatin-induced nausea and vomiting and QOL. Method: The antiemtic effect and QOL between one-day and two-day schedule of 3 mg/day of intravenous granisetron in cycle 1 and cycle 2 of cisplatin-based chemotherapy were compared. Frequency and severity of nausea/vomiting, QOL, oral intake and side effects were evaluated daily since day 0 to day 7 of chemotherapy.
Thirty eight patients were enrolled and 37 patients(31 male, 6 female, median age 60 with range of 42~74) were evaluable. The range of cisplatin were 50~l00mg/§³ and one or two of other chemotherapeutic agents such as 5FU, VP16, ifosfamide and mitomycin were combined. We evaluated the number of vomiting and QOL index with 10 items including nausea/vomiting and anorexia from day 0 to day 7 of chemotherapy. Twelve of 37 could not receive the G2 because of discontinuation of chemotherapy or patient's refusal of granisetron any more and eventually 25 had both Gl and G2. Time to first vomiting, control of vomiting and the amount of oral intake on day 1, day 2 and the worst day and side effects were not different between Gl and G2. QOL on day 2(G1; 56.2¡¾16.2 vs G2; 68.4¡¾20.3)(p<0.05) and change of QOL since day 1 to day 2 of cispltin(Gl; 16.3+2.1 vs G2 0.07+0.6)(p<0.01) were significantly different.
Although the additiional intravenous granisetron on day 2 of cisplatin-based chemotherapy did not control nausea/vomiting more successfully, it improved QOL on the second day and the change of QOL from day 1 to day 2.
Key words: Cisplation-induced nausea/vomiting, 5-hydroxy tryptamine-3 antagonist, Granisetron, One-day and two-day schedule, Prevention, Quality of life
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI